PHESGO is a combined fixed-dose subcutaneous formulation of pertuzumab and trastuzumab that requires just 20–38 minutes for administration and observation1
- Early breast cancer (eBC):1 PHESGO is indicated for use in combination with chemotherapy in:
• The neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence
• The adjuvant treatment of adult patients with HER2-positive eBC at high risk of recurrence
- Metastatic breast cancer (mBC):1 PHESGO is indicated for use in combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease
PHESGO produced non-inferior serum trough concentrations compared with PERJETA® (pertuzumab) IV and trastuzumab IV4
- FeDeriCa study design
- Serum trough concentrations
- pCR rates
PHESGO had a safety profile which is consistent with that of PERJETA IV and trastuzumab IV1
- PHESGO safety profile
- Most common adverse events
- Injection-related reactions
- Cardiac safety
- PHranceSCa study design
- Safety during crossover period
PHESGO can reduce administration and observation time by up to 92% compared with PERJETA IV and trastuzumab IV5
- Preparation and dosing
- Administration and observation
- Patient preferences
View a range of practical and informative resources for healthcare professionals and patients receiving PHESGO
- Administration video
- Dosing and administration guide
- Patient information booklet
- Transitioning from IV pertuzumab and trastuzumab patient leaflet
eBC, early breast cancer; HER2, human epidermal growth factor receptor 2; IV, intravenous; mBC, metastatic breast cancer; NHS, National Health Service; pCR, pathological complete response.
- PHESGO Summary of Product Characteristics.
- NHS England Cancer Drugs Fund List. Available at https://www.england.nhs.uk/cancer/cdf/cancer-drugs-fund-list/. [Accessed 2 June 2021]
- Scottish Medicines Consortium. SMC2364. July 2021.
- Tan AR et al. Lancet Oncol. 2021;22(1):85–97.
- Roche. Data on File. M-GB-00002430.
Date of preparation: July 2021.